S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:MRUS

Merus Stock Forecast, Price & News

$22.21
-0.73 (-3.18 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.02
$22.99
50-Day Range
$16.48
$27.23
52-Week Range
$11.19
$31.27
Volume63,263 shs
Average Volume119,341 shs
Market Capitalization$854.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59
30 days | 90 days | 365 days | Advanced Chart
Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.


Merus logo

About Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Headlines

Merus (NASDAQ:MRUS) Stock Price Down 3.7%
Merus (NASDAQ:MRUS) Stock Price Down 3.7%
September 22, 2021 |  americanbankingnews.com
Merus (NASDAQ:MRUS) Trading Down 3.7%
Merus (NASDAQ:MRUS) Trading Down 3.7%
September 22, 2021 |  americanbankingnews.com
Merus (NASDAQ:MRUS) Shares Gap Down to $27.10
Merus (NASDAQ:MRUS) Shares Gap Down to $27.10
September 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

498th out of 1,352 stocks

Pharmaceutical Preparations Industry

244th out of 665 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Merus (NASDAQ:MRUS) Frequently Asked Questions

Is Merus a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merus stock.
View analyst ratings for Merus
or view top-rated stocks.

What stocks does MarketBeat like better than Merus?

Wall Street analysts have given Merus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Merus?

Merus saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 2,690,000 shares, an increase of 26.3% from the July 29th total of 2,130,000 shares. Based on an average daily volume of 276,300 shares, the short-interest ratio is presently 9.7 days. Approximately 8.8% of the shares of the stock are sold short.
View Merus' Short Interest
.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Merus
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.13. The biotechnology company earned $12.38 million during the quarter, compared to the consensus estimate of $7.83 million. Merus had a negative net margin of 231.19% and a negative trailing twelve-month return on equity of 51.93%.
View Merus' earnings history
.

How has Merus' stock been impacted by Coronavirus?

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRUS shares have increased by 52.8% and is now trading at $22.21.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MRUS?

5 brokers have issued 1 year target prices for Merus' shares. Their forecasts range from $21.00 to $33.00. On average, they expect Merus' share price to reach $29.00 in the next twelve months. This suggests a possible upside of 30.6% from the stock's current price.
View analysts' price targets for Merus
or view top-rated stocks among Wall Street analysts.

Who are Merus' key executives?

Merus' management team includes the following people:
  • Bill Lundberg, President, CEO, CFO & Non-Executive Director
  • John de Kruif, Chief Technology Officer & Senior Vice President
  • Andrew Joe, Chief Medical Officer
  • Liu Hui, Chief Business Officer & Executive Vice President
  • Peter B. Silverman, Executive Vice President & General Counsel

What other stocks do shareholders of Merus own?

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (7.74%), Avoro Capital Advisors LLC (1.72%), Morgan Stanley (1.08%), Morgan Stanley (1.08%), Deutsche Bank AG (1.02%) and Millennium Management LLC (0.83%). Company insiders that own Merus stock include Bvf Partners L P/Il, Kruif John De, Lex Bakker, Mark Throsby and Value Fund L P Biotechnology.
View institutional ownership trends for Merus
.

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., FMR LLC, Morgan Stanley, Morgan Stanley, Ikarian Capital LLC, Deutsche Bank AG, Credit Suisse AG, and Avoro Capital Advisors LLC. Company insiders that have sold Merus company stock in the last year include Bvf Partners L P/Il, Kruif John De, and Lex Bakker.
View insider buying and selling activity for Merus
or view top insider-selling stocks.

Which major investors are buying Merus stock?

MRUS stock was purchased by a variety of institutional investors in the last quarter, including AXA S.A., Sphera Funds Management LTD., Millennium Management LLC, BlackRock Inc., Point72 Asset Management L.P., Citadel Advisors LLC, Marshall Wace LLP, and Marshall Wace LLP. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Merus
or or view top insider-buying stocks.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $22.21.

How much money does Merus make?

Merus has a market capitalization of $854.64 million and generates $29.94 million in revenue each year. The biotechnology company earns $-85,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Merus have?

Merus employs 117 workers across the globe.

What is Merus' official website?

The official website for Merus is www.merus.nl.

Where are Merus' headquarters?

Merus is headquartered at YALELAAN 62, UTRECHT P7, 3584 CM.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at (130) 253-8800 or via email at [email protected].


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.